Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | S100A4 | P26447 | 1/20 | 0.30 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3735042 | 0.84 | RXFP1 (0.42) | RXFP1HRH3NR4A2CYP1A2POLB | |
| SCHEMBL195410 | 0.82 | ALDH1A1 (0.42) | RXFP1CYP2C19NPC1RAB9AACHE | |
| SCHEMBL3745442 | 0.81 | RXFP1 (0.36) | RXFP1HRH3CYP1A2POLBCYP2C19 | |
| SCHEMBL11324116 | 0.81 | RXFP1 (0.36) | RXFP1HRH3POLBNPC1RAB9A | |
| SCHEMBL11056896 | 0.72 | PDE3B (0.38) | RXFP1HRH3OPRK1HTR3A | |
| SCHEMBL3741505 | 0.71 | LTB4R (0.32) | — | |
| SCHEMBL7608692 | 0.69 | NR4A2 (0.52) | RXFP1HRH3NR4A2CYP1A2POLB | |
| SCHEMBL11319351 | 0.68 | ESR1 (0.43) | CYP1A2POLBCYP2C19NPC1RAB9A | |
| SCHEMBL5382968 | 0.66 | RXFP1 (0.38) | RXFP1HRH3NR4A2CYP1A2CYP2C19 | |
| SCHEMBL11331470 | 0.64 | TDP1 (0.37) | RXFP1POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205311-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED | 2007-04-17 | — | — | US | disclosed |
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-03-31 | — | — | US | disclosed |
| EP-1474397-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003059885-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CCNK, TERT, CCNA1 | RXFP1 4321/4885HRH3 3219/4885NR4A2 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.